Ireland
--:--IST
Starting soon Not applicable

BARBED vs. STANDARD Suture for Colporrhaphy at the End of Laparoscopic Hysterectomy

NCT05833204 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2026-09-01
Last updated
2026-04-29

Condition(s) studied

Vaginal Cuff Complications

Investigational drug(s) / intervention(s)

Laparoscopic colporrhaphy with 0-caliber barbed absorbable sutureLaparoscopic colporrhaphy with standard 0-caliber absorbable suture

Laparoscopic colporrhaphy with 0-caliber barbed absorbable suture: After the total laparoscopic hysterectomy, the colporrhaphy will be performed using a 0-caliber barbed absorbable suture (V-Loc ™, Covidien, Medtronic)

Laparoscopic colporrhaphy with standard 0-caliber absorbable suture: After the total laparoscopic hysterectomy, the colporrhaphy will be performed using a 0-caliber absorbable suture made of a coated braided thread (Vicryl; Ethicon Inc, Sommerville, NJ)

Study summary

Hysterectomy is one of the most common surgical procedures performed worldwide, with more than 400,000 hysterectomies performed annually in the United States. As a consequence, even uncommon complications can affect large numbers of patients. Among potentially life-threatening events, vaginal cuff dehiscence complicates 0.14-1.38% of procedures, and any vaginal cuff complications (dehiscence, hematoma, bleeding, infection) are estimated to affect 4.7-9.8% of patients. In this scenario, any preventive strategy can provide clinically relevant benefits. Regarding colporrhaphy, only the adoption of a laparoscopic approach instead of a vaginal approach is supported by high-quality evidence. Our group demonstrated that the laparoscopic closure of the vaginal cuff after total laparoscopic hysterectomy reduces the incidence of vaginal cuff complications.

Among other potentially effective interventions, the use of barbed sutures was associated with a lower incidence of vaginal cuff dehiscence than the standard suture. In a recent meta-analysis, the use of barbed sutures has been associated with a pooled incidence of vaginal cuff dehiscence of 0.4% versus 2% after a traditional vaginal suture. However, this evidence is limited because most pooled studies were retrospective, and only two were randomized controlled trials. Moreover, these two randomized controlled trials had a very small sample size and were not powered to detect clinically relevant differences. On that basis, despite the promising utility of barbed sutures for vaginal cuff closure after total laparoscopic hysterectomy, the choice of the type of suture is not evidence-based but still guided by personal opinions, as well as by the preference and habits of the operators.

Therefore, this study aims to investigate whether the laparoscopic vaginal cuff closure with barbed suture determines a lower incidence of vaginal cuff dehiscence and complications than conventional sutures after total laparoscopic hysterectomy.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients undergoing elective total laparoscopic hysterectomy * Surgery performed for the treatment of benign pathology * Age \> 18 years * Surgery performed by laparoscopy * Signature of informed consent Exclusion Criteria: * Patients undergoing emergent surgery * Patients candidates for hysterectomy for oncological indication * Patients who underwent previous radiation therapy * Patients allergic to the suture material used in the study * Patients unable to express adequate informed consent to participate in the study

Primary outcome measure(s)

  • Vaginal cuff dehiscence — 30 days after surgery
    Any partial or total separation of the vaginal cuff
  • Vaginal cuff dehiscence — 90 days after surgery
    Any partial or total separation of the vaginal cuff

Trial sites (1)

FacilityCityRegionStatus
AOUI Verona - University of Verona - Department of Obstetrics and Gynecology Verona Italy
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05833204 on ClinicalTrials.gov ↗ ← All trials in Italy